Navigation Links
Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
Date:2/13/2013

vozanib versus patients who received sorafenib in the TIVO-1 study.  Additionally, four posters with tivozanib data regarding the safety and efficacy profile of tivozanib will also be presented at the meeting. A new drug application (NDA) for tivozanib, an investigational agent,  is currently under review by the FDA for the treatment of patients with advanced renal cell carcinoma.

"We applaud companies such as Astellas that are committed to developing medicines for difficult-to-treat cancers," said Helen Miller , LCSW, CancerCare CEO. "We share their commitment to put cancer patients first."

About Astellas

Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in oncology, and has several oncology products on the market and compounds in development. Astellas is proud to be an award recipient of the CEO Gold Standard Accreditation from the CEO Roundtable on Cancer. For more information on Astellas Pharma Inc., please visit our website at www.astellas.us.

About XTANDI® 

XTANDI® (enzalutamide) capsules is an oral, once-daily androgen receptor inhibitor. XTANDI was approved by the FDA on August 31, 2012 for the treatment of metastatic castration-resistant prostate cancer for patients who have previously received docetaxel (chemotherapy). A Marketing Authorization Application for XTANDI is currently under review by the European Medicines Agency (EMA).

The efficacy and safety of XTANDI were assessed in the randomized, placebo-controlled, global phase 3 AFFIRM clinical trial. A tota
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
2. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
3. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
4. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
5. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
6. First sales of DIFICLIRâ„¢ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. CTIA-The Wireless Association Highlights Connected Health Benefits and Potential
8. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
9. Philips Highlights Future Innovations at RSNA 2012 Transformation Lab
10. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
11. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 1 Abnormalities in auditory and language processing may ... using magnetoencephalography (MEG), according to a study presented today ... North America (RSNA). , , ... fields associated with electrical brain activity," said Timothy Roberts, ...
... whose eyes are misaligned and point outward are at significantly ... to findings of a Mayo Clinic study published this ... Academy of Pediatrics. , , ... with strabismus (misaligned eyes) and compared them with records of ...
Cached Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Eye Divergence in Children Triples Risk of Mental Illness 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... their effort to ensure,this generation of veterans is ... partnered with St. Johns, University School,of Risk Management, ... (IICF) on a three-day "Warriors to Work" Insurance,Industry ... wounded,warriors, most of whom were from the New ...
... is the best available option for people with hemochromatosis ... is often dismissed as a primitive form of medicine, ... of bad humors by draining the life-sustaining fluid. , ... is still the preferred means of treatment. , Hemochromatosis ...
... quality of care, communication and productivity,to new levels, while improving ... ... disciplines of care, PITTSBURGH, Aug. 25 Vocollect Healthcare ... retirement,community located in Wyomissing, Pennsylvania, will deploy AccuNurse(R),voice- assisted care ...
... Fitness tops competition on Inc. 5000 list ... rakes in revenue and new members, DOVER, N.H., ... for its "Judgment Free" atmosphere and friendly prices, earned,the ... 2008 list of,the 5,000 fastest-growing private businesses in the ...
... be racing faster this fall for every medical student in ... student and resident must pass will be delivered in a ... a skill that some say has become an Achilles heel ... doctors and residents out there taking this test know they ...
... and supplies to the EMS market, announced today the release of ... design first introduced to the EMS community in 1999. , ... ... [Hartwell Medical], a leading supplier of [emergency medical equipment] and ...
Cached Medicine News:Health News:Wounded Warrior Project (WWP), St. John's University, and Insurance Industry Charitable Foundation Partner to Assist Wounded Warriors 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 2Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 3Health News:N.H.-Based Health Club Operator Sets The Industry's Pace 2Health News:Listen up! 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 3
... name: ferumoxides) is Advanced Magnetics' contrast agent for ... lesions. It is the first organ-specific MRI contrast ... natural function, the agent is taken up by ... not in most tumors. The liver is a ...
... new Contrast Agent for Ultrasonography ... stabilized SF6 microbubbles. The size ... 1 and 10 m, and ... and 5 x 108 per ...
... in 1996, VISIPAQUE is the only isosmolar contrast ... osmolality equal to that of blood, VISIPAQUE was ... also the only contrast medium formulated with sodium ... In 1997, VISIPAQUE received FDA approval for use ...
... (iopromide) injection is a nonionic, iodinated, ... administration. Introduced in the U.S. in ... in Europe, ULTRAVIST today is ... has established a positive clinical experience ...
Medicine Products: